
==== Front
Int J Med Sci
Int J Med Sci
ijms
International Journal of Medical Sciences
1449-1907
Ivyspring International Publisher Sydney

10.7150/ijms.97485
ijmsv21p2065
Review
Telomeres and telomerase in Sarcoma disease and therapy
Huang Jin 12†
Feng Yan 12†
Shi YangJing 3†
Shao Weilin 12
Li Genshan 2
Chen Gangxian 2
Li Ying 2
Yang Zuozhang 2✉
Yao Zhihong 12✉
1 Department of Cancer Research Institute, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, Yunnan, 650118, China.
2 Bone and Soft Tissue Tumours Research Centre of Yunnan Province, Department of Orthopaedics, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, Yunnan, 650118, China.
3 Kunming Medical University, Kunming, Yunnan, 650500, China.
✉ Corresponding authors: Zuozhang Yang, E-mail: yangzuozhang@kmmu.edu.cn. Zhihong Yao, E-mail: yaozhihong@kmmu.edu.cn.
† These authors contributed equally.

Competing Interests: The authors have declared that no competing interest exists.

2024
6 8 2024
21 11 20652080
18 4 2024
24 7 2024
© The author(s)
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See https://ivyspring.com/terms for full terms and conditions.
Sarcoma is a rare tumor derived from the mesenchymal tissue and mainly found in children and adolescents. The outcome for patients with sarcoma is relatively poor compared with that for many other solid malignant tumors. Sarcomas have a highly heterogeneous pathogenesis, histopathology and biological behavior. Dysregulated signaling pathways and various gene mutations are frequently observed in sarcomas. The telomere maintenance mechanism (TMM) has recently been considered as a prognostic factor for patients with sarcomas, and alternative lengthening of telomeres (ALT) positivity has been correlated with poor outcomes in patients with several types of sarcomas. Therefore, telomeres and telomerases may be useful targets for treating sarcomas. This review aims to provide an overview of telomere and telomerase biology in sarcomas.

sarcoma, osteosarcoma
telomeres
telomerase
telomere shortening
TERT promoter mutation
==== Body
pmc1. INTRODUCTION

Cancers derived from mesenchymal cells are called sarcomas1. Sarcomas are a cluster of different nasty excrescences that occur in soft tissues and bone2. Histologically, osteosarcoma (OS) and soft tissue sarcoma (STS) are considerably different1, and they comprise 1% of all cancers. The incidence of sarcomas is 1-5 cases per 1 million people3. While making up just 1% of all cancers in humans, sarcomas are the second most common solid tumor type in children and adolescents4. A total of 20% of juvenile and 1% of adult solid malignancies are bone and STS malignancies, respectively. There are more than 50 different sarcoma subtypes, 50% of which affect the musculoskeletal system and arise in the extremities. Each subtype has great morphological and phenotypic heterogeneity and is highly diverse5. The skin, organs, and other soft tissues such as adipose tissue, muscle, nerve sheath, and blood vessels are frequent sites of STS development6. OS, Ewing sarcoma (EWS), and chondrosarcoma (CS) are the most common bone sarcomas (BS), accompanied by metastatic illness7. OS arises from osteoblastic cells. ES arises from round cells of the bone marrow, primitive neuroectodermal cells, or neural crest cells. CS are the most common types of bone cancer, which most likely originates from transformed chondrocyte cells developing from mesenchymal stem cells (MSC)8. OS usually develops in areas where bones grow quickly, particularly at the ends of long bones9.

It is difficult to make diagnosis for the variety types of sarcomas. Sarcomas occur in various forms, and each subtype typically exhibits distinctive manifestations. And, the same form of sarcoma may occur in different organs with greatly different clinical behaviors6. Different subtypes of sarcoma have different diagnostic criteria. While, the prognosis for most patients with sarcoma is poor. The 5-year survival rates of patients with non-metastatic and metastatic OS are 60% and 30%, respectively, owing to strong invasive capacity and primary metastasis10. Patients with EWS or CS have similar outcomes. To improve the survival rate and prognosis of patients and achieve better treatment results, it is essential to explore the pathogenesis of different sarcomas and screen targeted drugs. Repeated nucleoprotein structures known as telomeres are present at the boundaries of chromosomes. They are crucial for chromosomal end preservation, inhibition of DNA damage response (DDR), and preservation of genomic stability11. Tumor development may result from an anomaly in the telomere structure. One of the factors that causes cancer is telomere length. Both long and short telomeres maybe stimulate the growth of cancer. Telomere maintenance is an essential phase in carcinogenesis, including telomerase activation and selective telomere extension. It is interesting that telomere maintenance is frequently positive in many subtypes of sarcomas frequently linked with poor prognosis. The primary mechanism is telomerase overexpression. However, a small percentage of malignancies use a homology-directed repair-mediated telomerase-independent ALT mechanism12. The usage of ALT is common in some cancer types, such as OS and glioblastoma (GBM), occurring in approximately 5-15% of all human malignancies13. Although, RNA component called telomerase RNA (TERC) is widely expressed in healthy mortal physical cells, telomerase reverse transcriptase (TERT) is epigenetically suppressed, and its expression is thought to be a limiting factor in telomerase activity. Reactivated telomerase is estimated to be present in over 90% of human malignancies14. Telomerase activity is often elevated in bone and STS. Aberrant expression of TERT, a component of telomerase, is strongly associated with sarcomas15. Therefore, the telomeres and telomerases have important potential in treatment of sarcomas.

2. TELOMERES BIOLOGY IN SARCOMA

2.1. STRUCTURE OF TELOMERE

The last component of the linear chromosomes is the called telomeres16. The six-protein shelter in complex and telomeric DNA form complexes to form human telomeres17. Mammalian telomeres are made up of tandem TTAGGG DNA repeats that span many kilobases, about 10∼15 kb in humans and 25∼50 kb in mice18, 19. The telomere has a unique DNA design that consists of two components in extension to its repeating DNA property. A lengthy double-stranded DNA (dsDNA) region that ends in an unattached 3′ tail, was understood as the G-overhang20. The recurring sequence of nucleotides TTAGGG makes up the 3′ ends of chromosomes21. The coplanar arrangement of four guanine bases known as a "G-quartet" is held together by hoogsteen hydrogen bonds and kept stable by physiologically plentiful Na+ or K+ cations. G-quadruplexes can be created by stacking G-quartets depending on the number of strands involved, strand direction, and changes in loop size and sequence. These structures can adopt a broad range of topologies22. A 30∼400 base 3' overhang of the G-rich strand gives telomeres their distinctive appearance. What is known as a telomeric (T) looping procedure and a displacement (D) loop are created when the G-strand overhangs, fold back, and invades the double-stranded telomeric area. It has been suggested that the T-loop topology can shield chromosomal ends from telomerase activity, DNA repair, and degradation18, 19. DNA TTAGGG sequences were linked using shelterin23. The six subunits that make up the shelterin complex attach to telomeric DNA directly in three of them (TRF1, telomere repetition bound factor 1; TRF2, telomere repetition bound factor 2; POT1, the protective of telomere protein 1), and three of which mediate the interaction between components (TIN2, TRF1, and TRF2 interaction Nuclear Protein 2; RAP1, Repressor-Activator Protein 1; TPP1, and TIN2 Organized Protein)24. TRF1 and TRF2 have different surface interactions when bound to TIN2. Additionally, TIN2 binds to TPP1, which then binds to POT1 (POT1a and POT1 in mice). The six-subunit complex is formed when Rap1 binds to TRF2. Despite many documented alterations in the subunits, the binding surfaces between shelterin subunits have a variety of structural characteristics and most likely do not include post-translational modifications25. POT1 engages with the single-stranded telomeric overhang, whereas TRF1/2 interacts with double-stranded telomeric DNA. Through protein-protein interaction, the final three proteins connect to the telomeres26.

2.2. FUNCTION OF TELOMERES

To shield chromosomal tails from the DNA repair machinery, telomeres, which are dynamic nucleoprotein structures, create protective caps27. These sequences come together to create a cap that serves at least two protective purposes: (1) it enables cells to discriminate between double-strand breaks and chromosomal ends and (2) it prevents chromosomes from being destroyed, recombined, and fused end to end28. Loss of the cap renders telomeres indistinguishable from double-stranded breaks, resulting in checkpoint capture, telomere fusion, and unregulated deterioration29. The likelihood of genomic instability and tumorigenesis are considerably increased by this process30. Short telomere cells restart and accelerate transformation phenotypes if DNA damage response barriers, such as p53 loss, are overcome. In this situation, telomerase activity enables complete malignancy possible31. DNA polymerases' traits include the restriction of DNA replication to the sequence from 5' to 3' and the requirement of a primer, frequently RNA, to initiate the synthesis of DNA. When the terminal RNA primer is withdrawn, a gap at the 5' tails of freshly duplicated strands is left that cannot be addressed by a conventional DNA polymerase. As a result, when DNA replication cycles continue, telomere length gradually decreases, ultimately leading to the loss of genetic information29.

2.2.1. FUNCTION OF TELOMERE LENGTH

The telomeric environment, genetic variables, and related telomeric proteins such as telomerase affect the length of telomere32. According to a cross-sectional study, women who reported feeling stressed had telomeres approximately a decade shorter than those who reported feeling less stressed. Environmental variables (such as smoking, alcohol, drugs, and medicines) and lifestyle factors (such as obesity, exercise, and psychological factors) can be modified to enhance health outcomes, which may be partially attributed to telomere maintenance33. Since telomere length gradually decreases with each dividing cell in its lack of extension, telomere length is highly variable, regardless of whether it's within an individual cell. And it functions as a "molecular clock" of the proliferating lifetime of primordial cells20. A DNA damage reaction that causes senescence, persistent cell cycle arrest, or apoptosis in cells is signaled when only one or a tiny number of telomeres pass through an important barrier, potentially approximately 100 pairs of bases34. Inactivation of the tumor-suppressor proteins, p53 and Rb, can stop this process. Mutations in TP53 and RB1 were positively associated with telomere length35. Cells with severely short telomeres can continue to divide longer when p53 and RB are inactive. However, this leads to telomere crisis, a time when cells begin to die and the genome becomes unstable36. Numerous clinical problems, including a higher chance of developing schizophrenia, depression, cancer, diabetes, heart failure, cardiovascular illness, T-cell immunodeficiency, cognitive decline, and early death, are associated with a short telomere phenotype. However, melanoma, adult glioma, and chronic lymphocytic leukemia seem to be at an increased risk due to longer telomeres. In similar studies of pediatric malignancies, longer telomeres have been linked to an increased likelihood of OS and neuroblastoma28. In vertebrate models, there is strong evidence that long telomeres are predisposed to cancer. Long-telomere mice consistently performed poorly when the ability of oncogenes to cause tumors was examined in mice with short and long telomeres, such as when Myc or KRAS was overexpressed. These mice developed more aggressive tumors and had lower survival rates37. Telomere length is a significant limiting factor in how well telomeres can perform. To retain the ability of a cell to replicate for an extended period, telomere length must be maintained. There are two basic ways to accomplish this, either by the activity of the specialized enzyme telomerase or by ALT, which is mediated by homologous recombination38. Cancer cells can reproduce indefinitely because of telomere extension39. To prevent telomere shortening, protect telomeres from DNA damage repair mechanisms, and prevent senescence and/or apoptosis caused by telomeres, cells must develop TMM during carcinogenesis. Thus, telomere upregulation is crucial for cancer development40. Human carcinomas contain telomeres that are noticeably shorter than those in normal tissues, and early stages breast tumors have been found to have telomere-to-telomere fusions. Patients with early stage chronic lymphocytic leukemia are more likely to have telomere dysfunction than those in the later phases of the disease, which are marked by telomere-to-telomere fusion41.

2.2.2. FUNCTION OF SHELTERIN

The capacity to sustain the shelterin complex is now widely acknowledged to be lost when telomere length is dangerously low. The release of the shelterin complex's inhibitory effect on the reaction to DNA damage pathways causes the cell phase to leave G1 and enter G038. Telomere stability is guaranteed by crucial and unique tasks performed by the shelterin complex. TRF2 is necessary, for instance, to generate T-loops and maintain DDR and non-homologous end-combining inhibition through ataxia telangiectasia mutated (ATM). Whereas POT1 and TPP1 work together to attach to the single-stranded 3′ overhang and prevent the recruitment of replication protein A to decrease ATR-mediated DDR, TRF1 has a significant impact on the regulation of telomeric DNA replication. Because TIN2 stabilizes the interactions of TRF1 and TRF2 with telomeric DNA and connects the TPP1/POT1 heterodimer to TRF1 and TRF2, it is crucial for shelter complex stability. RAP1 interacted with TRF2 to enhance telomeric DNA-specific binding42. According to recent studies, mutations in the shelterin complex may cause a variety of malfunctions, eventually contributing to the development of human tumors. It is noteworthy that shelterin gene mutations in melanoma, glioma, sarcoma41, cardiac angiosarcoma (CAS), Li-Fraumeni-like syndrome (LFLS), colorectal cancer, Hodgkin's lymphoma37, mantle cell lymphoma, and parathyroid adenoma reveal extensive possible importance in the development of non-epithelial cancer43. Thirteen carriers of C4 or C5 variants were found in four of the six canonical genes in the shelterin complex: POT1 (6), TERF1 (2), TINF2 (3), and TERF2IP (2). Furthermore, the cancer incidence was similar to that of TP53, but higher in the families of shelterin probands having C4 or C5 variants. In probands with sarcoma, the relative leukocyte telomere length (RLTL) gradually decreased over time, independent of exposure to radiation or chemotherapy. The RLTL of shelterin variant carriers was longer than that of other cohort members, despite their similar ages at first cancer diagnosis. Sarcoma is more likely to occur than other epithelial malignancies because of heritable abnormalities in telomeres and mitotic functions. Most sarcomas were genomically unstable. Replication stress caused by ALT results in genomic instability, which sends a signal to TP53, a gene closely associated with sarcoma susceptibility. 0.8% sarcoma probands had TP53 mutations, whereas 3.2% had C3 to C5 polymorphisms in the shelterin complex 15. It was shown that a missense mutation (p.R117C) in the POT1 gene was the cause of CAS44. Angiosarcoma (AS) exhibited a POT1 mutation 11 times more frequently than other tumors. Patients with LFLS and spontaneous AS have been shown to carry five harmful POT1 variations. Each conserved domain contained POT1 mutations. Given the high frequency of POT1 mutations in AS, it is likely that a key factor contributing to the formation of AS is the loss of POT1 function. Therefore, POT1 analyses should be prioritized in AS sequencing investigations45. POT1 mutant proteins lose their ability to bind single-stranded DNA and TPP1. When telomeres are abnormally long, function is lost46. ATR-dependent DNA damage signaling is activated by both damage response malfunction and POT1 gene function inhibition 47. A study discovered that, in comparison to POT1 wild-type, POT1 PVs had a considerably increased incidence of sarcoma and melanoma 48. The broad range of POT1 gene variations that cause cancer in many tissues indicates the universal significance of these genes. POT1 analysis should be regarded as a standard diagnostic procedure for these malignancies46.

2.3. TELOMERES AND SARCOMAS

Liposarcoma (LPS), leiomyosarcoma (LMS), and undifferentiated pleomorphic sarcoma (UPS) are the three most prevalent types of STS 49. Sarcomas and gliomas have longer telomeres than other cancers, whereas tumors have shorter telomeres than normal tissues35. The risk of STS is greatly increased by longer telomeres in peripheral blood leukocytes50. The chances of lymphoma, OS, and STS have been found to be higher in patients with a long leukocyte telomere length. It has been shown that the largest correlation was shown in gastrointestinal stromal tumor (GIST), where a 2.2-fold higher risk was associated with longer LTL. In LMS, it was significant, but not for LPS or angiosarcoma. Unknown biological factors underlie the association between increased cancer risk and longer LTL. Recent studies have shown that both short and long telomeres promote cancer development. Telomere disruption may contribute to the development of cancer. Telomeres that are abnormally short can promote chromosomal end-to-end joining, which can result in genomic instability and cancerous changes. In contrast, extremely long telomeres may increase the risk of cancer development by promoting prolonged cell division and delaying cellular senescence and apoptosis, creating a setting that favors the development of genetic defects. The unique tissue genesis of sarcomas may be another biological factor contributing to the substantial correlation between extended LTL and high STS risk. Sarcomas are malignant tumors originating from the mesenchyme, in contrast to carcinomas, which start in epithelial cells. While mouse and pediatric human malignancies are mostly sarcomas and lymphomas, adult human tumors are primarily epithelial carcinomas51. To enable immortalization, telomere shortening forces tumor cells to trigger a TMM52, 53. Sarcomas that often test positive for ALT include OS, LMS, LPS, and undifferentiated pleomorphic sarcomas (malignant fibrous histiocytoma)54. Inherited abnormalities in telomeres and mitotic function raise the likelihood of sarcomas in comparison to most epithelial malignancies. Chromosome integrity depends on mitosis and telomere maintenance. Sarcomas are primarily characterized by genomic instability and use an alternative mechanism called ALT. Through replication stress, ALT induces genomic instability and TP53 signals, which are closely associated with sarcoma susceptibility. TERF1, TINF2, and POT1 are associated with sarcoma15. By continuously transplanting Pot1b-/- in mice, POT1b's function in controlling the maintenance of telomere length was examined. Early Pot1b-/- tumors initially had shortened telomeres, whereas late-stage Pot1b-/- cells exhibited significantly elongated telomeres, which are recognized as DNA damaged by the replication protein A (RPA) complex. Telomere extension is a result of telomerase recruitment being encouraged by the RPA-ATR-dependent DNA damage response at telomeres. POT1b inhibits the DNA damage response by unfolding G-quadruplex structures within stretched telomeres, which POT1a is not able to do. This suggests that the phenotypes observed in human cancers with POT1 mutations may be caused by similar mechanisms55. ALT is a more important TMM in LMS than telomerase activation. 31 LMS, 53% tested positive for ALT expression. Additional research has demonstrated a correlation between ALT-positive LMS and tumor necrosis, poor differentiation, high FNCLCC grade, and epithelioid/pleomorphic cell shape54. Most ALT cell lines exhibit signs of p53 pathway malfunction, most frequently due to TP53 mutations or viral oncoprotein-mediated p53 degradation. Mutations that inactivate ATRX are frequently observed in ALT malignancies; however, in zebrafish, ALT tumors are produced by both ATRX and TP53 knockouts, but ATRX knockouts do not activate ALT. Finally, telomere replication stress and dysfunction cause the ALT phenotype; however, when p53 is functional, it causes growth arrest and/or apoptosis. Although p53 pathway changes are frequently observed in ALT cells, p53 inactivation by itself is unlikely to cause ALT alone because most TP53-mutant malignancies are telomerase-positive (TA+)56. ALT-specific molecules, such as C-circles, are the only known molecules. For rolling-circle amplification, the C-circles are self-primed telomeric C-strand templates. Diverse centrifugation methods have been used to separate extracellular vesicles from the growth media of lung adenocarcinoma, GBM, neuroblastoma, OS, and STS cell lines. Of these, it was discovered that the exosome fractions from 11 ALT+ cancer cell lines included C-circles, whereas the normal fibroblast strain and the eight telomerase-positive cancer cell lines did not have any extracellular vesicles in their extracellular fractions. C-circles secreted by ALT+ cancer cells in exosomes exist as durable blood-based biomarkers and are possible clinical diagnostics for ALT activity57. GID4 and RAD51B are involved in telomere elongation in sarcomas58. The major outcome examined was the risk of mortality, which was computed as the number of deaths divided by the total number of participants during follow-up in ALT+ vs. ALT- individuals. These findings suggest that ALT is associated with a higher risk of mortality in patients with sarcomas. ALT levels should be considered when designing prospective therapies and performing precise prognostic stratification of these neoplasms59.

2.3.1. TELOMERES AND OS

Children, teenagers, and young adults are most frequently affected by OS60. 10%-15% of patients with newly diagnosed OS detected the metastatic disease, mostly in the lungs61. ALT is a common finding in 5-15% of human malignancies and is frequently linked to a poor prognosis, especially in OS and GBM62. In particular, the highest incidence of any tumor that has been studied exhibits ALT features in over 60% of OS cases52. Candidate gene analysis and genome-wide association studies (GWAS) have revealed potential risk variations in European-heritage individuals. In a multi-ethnic sample of children who were non-Hispanic white, Hispanic, African-American, or Asian/Pacific Islanders, an independent multi-ethnic dataset investigated the previously documented association between genetic susceptibility to longer LTL and the risk of OS. The result revealed that the highest impact was observed in Hispanic participants, and that genetic predisposition to prolonged LTL is a risk factor for OS63.

2.3.2. TELOMERES AND STS

Many different subtypes of LPS exist, each with its own characteristics64. In dedifferentiated liposarcomas (DDLPS), alternative telomere lengthening is a predictive indicator of poor prognosis. Telomerase activation is the major method of telomere maintenance in myxoid liposarcomas (MLS), whereas ATL is used for pleomorphic and DDLPS65. Telomeres are promising therapeutic targets for DDLPS. Targeting G4 structures may be an attractive and novel treatment for DDLPS and merits further research. Thus, G4 ligands are promising therapeutic agents for this condition66. LMS, accounts for 10% of all STS and affects individuals of all ages. It is a malignant tumor of smooth muscle origin that most frequently affects the uterus, retroperitoneum, and major blood vessels. Approximately 40% of the patients eventually develop local recurrence and/or metastasis. Patients with disseminated LMS are typically uncurable condition67. LMS that tested positive for ALT had tumor necrosis, epithelioid or pleomorphic cell shape, poor differentiation, and a high FNCLCC grade54.

3. TELOMERASE BIOLOGY IN SARCOMA

3.1 STRUCTURE OF TELOMERASE

In order to emphasize its capability to add telomeric sequence repeats, telomerase was given the name "telomere terminal transferase" when it was first identified in 198568. Telomerase is a ribonucleoprotein (RNP) complex that includes TERT, TERC, and several auxiliary proteins69. By catalyzing the extension of the 3′ end of the telomeric DNA, telomerase keeps the length of the telomere constant. During S phase, both components functionally associate in the nucleus with the temporary assistance of a number of other elements70. These two molecules mediate the canonical function of telomerase. After TERC attaches to the single-stranded overhang at the telomere, a hexameric repeat is added and used as a template by TERT for reverse transcription. Telomere elongation is made possible by reverse transcription and the repeated translocation of TERT and TERC to the 3′ end of the chromosome71.

3.1.1. HUMAN TELOMERASE REVERSE TRANSCRIPTASE (hTERT)

In humans, TERT is located on chromosome 5p15.33. The TERT gene has a 260 bp promoter core and is 42 kb long with 15 introns and 16 exons. Five to nine exons encode the reverse transcriptase domain. 22 different isoforms of the TERT transcript isoforms have been created72. TERT is composed of an RNA-binding domain (RBD), conserved reverse transcriptase (RT), a carboxy-terminal element (CTE), and an additional reverse transcriptase. Together, these domains constituted the TERT ring structure. In addition, it has a lengthy linker that connects the RBD to the telomerase amino-terminal domain (TEN)73, 74. Surprisingly, the TERT regions of promoters exclude the TATA and CAAT boxes while being rich in binding structures for numerous transcription variables, including the MYC oncogene (E-box) and Sp1 (GC box)75. Secondary DNA structures, called G-quadruplexes, are formed when guanine nucleotides are repeated. Within its core promoter, the hTERT promoter contains nine putative tandem G-quadruplex-forming regions76. Telomerase activity was constrained using TERT77. TERT is a specialized reverse transcriptase that differs from conventional reverse transcriptases in promoting template realignment to continue the synthesis of numerous DNA repeats without separating them from the telomere. TERT is a widely recognized therapeutic target because it is expressed only in cells with telomerase activity and not in a large number of healthy somatic cells78. Increasing TERT copying quantity, TERT gene amplification, genomic rearrangements, long-range interactions, and numerous point mutations in the TERT gene's promoter region include known methods of TERT reactivation that can boost TERT mRNA expression and TERT protein synthesis79. It is currently known that 19 percent of malignancies include single-base mutations that produce de novo binding sites in the proximal hTERT promoter for the ETS group of transcriptional components, resulting in gene reactivation. The T-INT1 region of the genome, which is 260 kb upstream and contains multiple binding motifs for GA-binding proteins (GABP) and members of the ETS transcription factor family, is necessary for the long-range chromosome connection necessary for the reactivation of the modified hTERT agents for promotion. By activating the molecular mechanism of WT-hTERT, researchers discovered that WT-hTERT transcription is active in CRCs and requires the transcription factor JunD, which belongs to the AP-1 family. The creation of Sp1-Sp1 tetramers within the proximate WT-hTERT promoter and a distant regulatory chromatin region, which we refer to as tert-interacting region 2, is made possible by increased amounts of JunD that foster a favorable chromosomal structure80. In contrary to wild-type promoters, TERT transcription is driven by the enrichment of active histone marks, which are mediated by long-range chromatin interactions, and the transcription element GABPA is exclusively recruited to mutant TERT promoters81. TERT was found to be expressed in 73% of 6,835 tumors and was linked to TERT point mutations, rearrangements, DNA amplifications, and transcript fusions, in addition to being predictive of telomerase activity. TERT promoter methylation is another route of deregulation of TERT expression35. Genomic analysis revealed, for the first time, the presence of TERT amplification and ATRX mutations in a subset of high-grade and dedifferentiated CS (20%), along with TERT promoter mutations. These abnormalities in telomere genes co-occurring with IDH1/IDH2 mutations and CDKN2A/2B loss or TP53 mutations suggest the potential associations and synergistic effects of these genes on CS progression82. Regarding TERT mutations, tumors with IDH1 or IDH2 mutations exhibit notably distinct genetic pathways and consequences. Thus, prognosis and clinical surveillance may be guided by diagnostic testing for TERT mutations83. Myxoid/round-cell LPS had a much higher enrichment of mutations in the TERT promoter (88%). TERT promoter mutations were not linked to tumor grade84. TP53/pTERT abnormalities may be used as molecular markers to indicate the origin of cells from hepatocellular carcinoma or mixed hepatocellular cholangiocarcinoma, as genetic alterations are maintained during sarcomatous transformation85. To investigate the previously unexplored genetics of these tumors, targeted next-generation sequencing and DNA copy number analysis through comparative genomic hybridization were performed on 40 pleomorphic dermal sarcomas. More than half of the samples had verified TERT promoter mutations86. Sanger sequencing was used to examine 116 patient samples identified as having 22 different histological subtypes of bone and STS, to check for TERT promoter mutations. Mutations in the TERT promoter were found in seven distinct sarcoma subtypes, with an overall incidence of 9.5%87. The study showed the TERT promoter hotspot mutation was not significantly correlated with clinicopathological characteristics or overall or metastasis-free survival. TERT aberrations may arise early in life and contribute significantly to tumor development, although they are not predictive factor14. An identical mutation was observed in both components of the five matched conventional CS and in high-grade components with TERT mutations88. A multi-center database study was conducted to describe the genomic landscape of gliosarcoma (GS) which found that 92% of cases of GS have mutate in the TERT promoter 89.

3.1.2. HUMAN TELOMERIC RNA COMPOENT (hTERC)

The TERC gene on chromosome 3q26 encodes a part of the human telomerase RNA component (hTERC or hTR)90. The length of TERC, which ranges from 150nt in ciliates to >2000nt in certain yeasts, is extremely diverse in contrast to the comparatively conserved TERT. The rapid development of the noncoding RNA (ncRNA) TER, explains this. The template/pseudoknot domain (t/PK), which generates a circular shape with the template and pseudoknot, and the stem-terminus element (STE), which comprises a hairpin, are the two sections of TERC preserved for interaction with TERT73. All hTERCs contain a brief sequence complementary to the telomeric TTAGGG hexanucleotide repeat sequence, although they differ in size and sequence depending on the species. However, the structures of hTERCs are highly conserved. The hTERC is a short (451nt as opposed to >1000nt in yeast)30. The G-rich region at the 5′ end of TERC, the RNA component of telomerase that houses the template sequence for completely new production of telomeric repetitions, has the potential to fold into a G-quadruplex. The creation of a helical region vital for determination of the template border in mammalian telomerase is thought to be hindered by this structure, which is also thought to protect TERC from degeneration during the initial phases of telomerase ribonucleoprotein synthesis91. In contrast to TERT, the expression of which is strictly controlled, TERC is widely expressed in both healthy and malignant tissues. The 5′ pseudoknot structure that interacts with TERT contains a region that functions as a template for telomere synthesis, making up the primary functional domain of TERC78. The primary function of TERC is to aid the extension of telomere by acting as a scaffold and template for telomerase RNP92. The 3' H/ACA short nucleolar RNA-like domain of TERC is composed of the ACA box at the 3' terminal tail and the H box in the single-stranded hinge region after the 5' hairpin. DKC1, GAR1, NHP2, and NOP10 are examples of H/ACA accessory proteins in the telomerase complex that bind to the TERC H/ACA motif to stabilize it and improve the TERC-TERT interaction. Pseudouridylation of TERC is the mechanism by which these H/ACA proteins stabilize TERC 93. Although TERC is found in germline tissues and telomerase-positive tumor cells, it is also expressed in normal somatic cells. Furthermore, it is expressed in tumor cells that lack telomerase and uses the ALT route to preserve telomere length. Research on tumor grade, aggressiveness, progression, and differentiation of lesions into high- and low-risk groups has demonstrated the clinical significance of TERC amplification in cancer92.

3.2 FUNCTION OF TELOMERASE

In most eukaryotes, telomerase is a crucial reverse transcriptase required for the maintenance of linear chromosomes94. Each time a cell divides, telomeres shorten; however telomerase prevents this from happening95. Cell immortality, or the ability of cells to multiply perpetually, is a property conferred by telomerase96. Telomeric DNA complies with the TERC once telomerase and telomeres join. Then, telomerase moves its RNA template to the new 3' telomeric end without separating from the telomere and adds one telomere repeat de novo to the 3' DNA end41. Cell proliferation is facilitated by the well-described canonical function of telomerases, which is to preserve the integrity of chromosomal end structures (telomeres)78. A thorough understanding of telomerase assembly and control has direct biological implications, because telomerase is frequently elevated in human malignancies. In addition, telomerase is related to a group of RNP enzymes that regulate a wide array of cellular functions, including the synthesis of proteins on the ribosome and processing of messenger RNA by the spliceosome. Telomerase also functions as an effective model system for comprehending the fundamental principles that regulate RNP structure and function, because each of these crucial RNP complexes depends on the precise interdependence of protein and RNA components97. While somatic cells lack telomerase activity, stem cells and most cancer cells do98. Cancer is characterized by cell proliferation, making treatment measures desirable. Additionally, because the enzymatic activity of telomerase ensures that both primary and metastatic tumor cells have an endless capacity for cell division, it appears to be a natural target for the development of cancer therapies99.

3.2.1. FUNCTION OF TERT

The TERT gene is tightly suppressed at the transcriptional level in a large number of differentiating human cells, which is caused by telomerase silencing in these cells despite the widespread expression of TERC in human cells. A key mechanism for telomerase activation throughout the tumorigenic phase is the de-repression of TERT, which induces TERT expression100. Chromosome ends are added to a six-base DNA repeat via hTERT reverse transcriptase activity, which prevents them from shrinking because of subsequent cell division101. In human somatic cells, telomerase activity is downregulated when TERT is silenced102. Critical telomere attrition eventually causes DDR, which induces cell cycle arrest and senescence of replication or apoptosis through p53 or RB tumor suppression mechanisms103. Most malignancies are characterized by elevated TERT27. TERT's abnormal TERT expression is linked to 85-90% of the malignancies that have been studied, despite the fact that it is ordinarily undetectable in somatic cells (apart from stem cells). For over 20 years, TERT has been recognized that TERT is a target for cancer treatment because of its exclusive expression in cancer cells104. Through a variety of processes, including amplification of the hTR-encoding genes TERC and TERT, telomerase activity increases in cancer. The development of non-coding mutations in the TERT promoter is the best-understood mechanism by which malignancies boost TERT transcription36. Numerous human cancer types, such as thyroid carcinomas, thyroid squamous cell carcinomas, gliomas, renal cell carcinomas, melanomas, urothelial carcinomas, oral squamous cell carcinomas105, bladder cancer, melanoma on the skin, basal cell carcinoma, oligodendroglioma, hepatocellular carcinoma36, and LPS106 exhibit hTERT overexpression. The cellular location, transcriptional control, and holoenzyme assembly are believed to contribute to the regulation of hTERT activity76. Heterozygous point mutations in the TERT promoter trigger TERT transcription. Beyond the TERT translation start location, at positions -124 and -146, correspondingly, the two most frequent activating mutations are both cytosine to thymine mutations (-124C>T and -146C>T)107. In mitosis, CDK1 phosphorylates hTERT, and this phosphorylation event impacts RNA-dependent RNA polymerase activity rather than hTERT function at telomeres108. Interestingly that in tumors with a high incidence, such as lung, breast, prostate, and colorectal cancers, TERT promoter mutations are either absent or were found only extremely rare. Overall, compared to tissues with strong self-renewal (such as bone marrow and colon), tissues with low self-renewal (such as the liver, brain, and bladder) appear to have a higher frequency of TERT promoter mutations77.

3.3. TELOMERASE AND SARCOMAS

Cell division in normal cells results in cell cycle arrest and death associated with senescence, which lack telomerase activity, by shortening chromosomal telomere ends. Telomerase is regularly and routinely active in bone and soft tissue sarcomas but not, in normal tissues. Telomere elongation induced by telomerase activation allows telomerase-positive sarcoma cells to proliferate indefinitely, even after cell division109. In the majority of cancers (85-90%), telomerase is used to preserve telomere length. The TERT gene, which encodes the catalytic portion of the telomerase riboprotein complex, has recently been found to be subject to recurrent mutations, which are the key mechanisms of telomerase activation54. As a malignant bone tumor, CS is the second most prevalent kind. Activating TERT mutations have recently been described as a common mutation in high-grade CS. They examined the predictive value of TERT promoter mutations in 241 CS patients gathered during a 24-year period (1994∼2017). Subsequent to the microdissection of 135 CS in 106 individuals, the TERT promoter was sequenced with information from the precursor cohort. Forty-five percent of patients had TERT promoter mutations at -124 C > T, which were substantially linked to shorter metastasis-free life, disease-specific survival, and higher tumor grade. Furthermore, tumors with TERT promoter mutations are connected to a more combative metastatic pattern. Patients having primary tumors of the wild type have shorter survival times, and metastatic mutations indicate tumor progression110. The genetic features of multiple sclerosis include a high frequency of hotspot mutations (C228T or C250T) in the promoter region of TERT, which encodes the TERT protein, and FUS-DDIT3 or EWSR1-DDIT3 gene fusion. The former triggers telomerase reactivation, a telomere maintenance process14. According to one study, TERT promoter mutations were frequently recurrent in MLS (29/39; 74%) and were not linked to the phenotype (myxoid vs. round cell variation), tumor grade, tumor location, median age, or sex of the patients in the current MLS series. This indicates that telomere maintenance, particularly in MLS, is significantly influenced by increased telomerase expression111. Previous studies examined the relationship between telomere length and TERT promoter mutations in the MLS sarcoma subtype. TERT promoter mutations most likely develop in a fraction of patients with MLS, with critically short telomeres as a subsequent event, most likely reflecting a compensatory mechanism that enables telomeres to lengthen or remain. Further research is required to fully examine the effects of telomere length and TERT promoter mutations on clinical outcomes, more research is required87. LMS do not exhibit TERT promoter mutations. However, TERT promoter mutations are, merely one mechanism of telomerase activation. It is unknown whether telomerase activity in LMS is triggered by other pathways54. Most people malignancies, including bone and soft tissue sarcomas, frequently exhibit active hTERT expression112. High-grade conventional CS frequently harbor mutations in the hTERT promoter gene. TERT promoter mutations appear to be key factors in the development of CS113. High tumor grade, metastatic disease, and mortality were all significantly correlated with the TERT promoter mutation, which was a poor prognostic indicator110, 113. TERT promoter mutations are simple to evaluate, and offer considerable promise as reliable clinical prognostic indicators and prospective therapeutic targets for telomerase-targeting strategies. In situations where morphology is equivocal, TERT promoter mutation analysis may be used as an adjunct to regular pathology to identify high-grade regions110. According to previous studies, TERT is a strong risk factor for OS and may promote cancer growth and spread. Diverse cell death pattern-related signatures for predicting prognosis and drug sensitivity in OS patients. In patients with OS, telomerase expression in the initial tumor samples is linked to lower progression-free and overall survival114. Sensitive and reliable telomerase activity analysis is essential for the clinical diagnosis, treatment, and prognosis of OS115.

4.TREATMENT OF SARCOMAS TARGETING TELOMERES AND TELOMERASE

Targeted therapies are becoming increasingly important in oncologists' toolkits as the molecular processes that cause sarcomas have been identified. Future clinical trial designs must consider this molecular understanding and make use of carefully chosen biomarkers to help determine the best targets for inhibition, as well as predictive and prognostic aspects116. STS is an uncommon and diverse group of tumors. Therefore, our therapeutic strategy is neither histology-specific nor generally standardized. The variability of these tumors has hampered the development of evidence-based treatment methods49. Modern approaches such as immunotherapies and medications that target epigenetic pathways are now being researched to enhance the results for this group of people117. Currently, children and adolescents are most frequently affected by OS, which is a very aggressive bone tumor118. Neoadjuvant MAP chemotherapy, together with further rounds of chemotherapy administered after the patient has recovered from surgery (adjuvant postsurgical chemotherapy), is the most popular treatment for young patients with resectable OS61. However, standard chemotherapy regimens are frequently ineffective in treating OS, and the use of drugs for tumor chemotherapy can have several negative side effects118. Over the past four decades, patient outcomes have remained consistent when localized OS is treated with established three-drug chemotherapy regimens119. Approximately 40% of OS cell lines test positive for ALT, making them resistant to the majority of chemotherapy treatments, and the lack of anti-cancer treatments that target ALT makes treating OS in the clinic even more difficult118. Targeting telomerase has several benefits over most other cancer targets, including potential cancer stem cells, due to its ubiquity, importance, and selectivity for cancer cells. Although there is a telomerase-independent ALT mechanism for maintaining telomeres in cancers and cell lines where telomerase is inactive or suppressed, some studies have indicated that ALT cells are less biologically active than telomerase-positive cancer cells and may be more vulnerable to medications that cause oxidative stress120. Telomerase is a prime candidate for cancer therapy121. One effective anti-cancer drug for the management of bone and STS is an oncolytic adenovirus that targets telomerase122. Telomerase can be targeted through immunotherapies that target TERT tumor-associated antigens, small-molecule inhibitors, or oligonucleotides that directly bind telomerase and prevent telomere extension 103.

4.1. TARGETING TRF1

Cancer cells are eliminated by TRF1 inhibitors like ETP-47037 and ETP-47228 because they obstruct TRF1 binding at the telomere point and stop the formation of the shelterin complex26. Recently, a new TRF1-targeting method was developed for inducing telomere dysfunction. This method is independent of the telomerase activity and length. Although further clinical studies are required to determine the effectiveness of pharmacological inhibitors that uncap telomeres in human cancer, these approaches provide new avenues for the development of anti-cancer drugs123. An innovative method for addressing telomeres in cancer cells was made possible by a study that produced a proof-of-concept, TeloTAC, which selectively breaks down TRF1 and TRF2 and interferes with telomerase function. Compared to normal cells, the cytotoxicity of the prototype TeloTAC 15b was much greater because of the effective degradation of TRF1 and TRF2. Therefore, the TeloTAC technique is useful as a new PROTAC approach that targets cancer. However, TeloTAC has several limitations due to the nature of these nucleotide oligomer-based designs, particularly in terms of potential clinical translation124.

4.2. SMALL MOLECULES AS TELOMERASE INHIBITORS

Currently, few effective hTERT inhibitors are available on the market. Among the active site inhibitors unique to hTERT with the greatest potential yet is BIBR1532, also known as 2-[E]-3-naphtalen-2-yl-but-2-enylylamino]-benzoic acid. A number of BIBR1532 research have revealed that telomerase is dose-dependently inhibited by increasing doses of BIBR1532, whereas no discernible effects were observed in normal human cells125. The artificial mixed-type noncompetitive non-nucleoside telomerase inhibitor BIBR1532 targets the telomerase catalytic subunit hTERT, with an IC50 value of 93 nM. Although its precise mode of action remains unknown, it may prevent telomerase translocation. Cancer cells undergo apoptosis and senescence in response to BIBR1532126. BIBR1532 selectively hinders DNA substrate elongation during template copying rather than the fundamental steps of template copying. Long-term therapy with BIBR1532 caused considerable telomere shortening and an 80% reduction in TA in CS cell lines 125. The results showed that treatment with BIBR1532 led to telomerase inhibition, reduced telomere length in telomerase-positive CS cells, and decreased their growth capability127. A 13-mer oligonucleotide called GRN163L(imetelstat) functions as a direct antagonist of the telomerase RNA template, attaching to the active site of hTER with high specificity and affinity to completely suppress the enzyme125. It has also been demonstrated both in vivo and in vitro that GRN163 is a potential anti-cancer agent that targets telomerase activity. GRN163 causes tumor cells to shorten their telomeres, which is followed by cellular senescence or apoptosis128. Imetelstat has shown the most promise when combined with other chemotherapeutic drugs, such as trastuzumab, 3-aminobenzamide (3AB) or traditional radiation therapy 129. GRN163L has been used in several clinical trials 125. Subsequent research on imetelstat is needed to explore its potential for the synergistic targeting of hTERT when used in conjunction with other medications, such as small-molecule inhibitors, which simultaneously minimize adverse effects and target other sources of cancer aggressiveness 129. The ideal dose of imetelstat in phase II for kids with solid tumors that come back or are resistant was investigated in a previous study130. Imetelstat increases telomerase suppression by the HSP90 inhibitor alvespimycin. The capacity of the HSP90 inhibitor alvespimycin to enhance the telomerase inhibitor's impact was evaluated as the chaperone molecule HSP90 promotes the assembly of telomerase proteins. However, the combination treatment group showed the strongest effect 131. K Trieb et al. reported that hyperthermia may offer a fresh adjuvant tactic for treating patients with OS by inhibiting telomerase activity. These findings demonstrate that OS cells undergo telomerase activity that is reversibly downregulated in response to heat132.

4.3. G-QUARDRUPLEX STABILIZERS AS TELOMERASE INHIBITORS

In order to prevent invasion and annealing of telomeric single-stranded DNA, the development of a G-quadruplex in the 3′-terminus of telomeric DNA may be useful as an anti-ALT cancer treatment. Therefore, a chemotherapeutic agent that precisely targets the telomeric G-quadruplex, in addition to having strong anti-tumor effects, may be more beneficial in the treatment of OS118. G-4 stabilizers offer a great deal of promise as anti-cancer therapies because of their high tolerance in in vivo experiments and ability to disrupt telomere structure by blocking the telomerase-binding proteins TRF2 and POT1126. One of the best compounds for telomeric G4 stabilization is the pentacyclic acridine compound RHPS4133. In addition to other modifications, aggressive tumors overexpress K+ membrane ion channels that lower the roughly 60 mM intracellular K+ concentration. Studies conducted in vitro have demonstrated that at such K+ concentrations, G4 structural alterations are still imperceptible, but their overall stability is decreased. Therefore, accurate and effective G4 DNA stabilization and anti-cancer medication administration could possibly be achieved using novel anthraquinone chemicals linked to distamycin analogs134. Quinazoline molecules specifically stabilize G4 complexes in vitro and in human cells. But no successful clinical trials have yet been the result of it135. Chemical substances known as G4 ligands maintain G4s stable. Streptomyces anulatus produces the natural G4 ligand, telomestatin, which binds to G4s and prevents telomerase activity. Telomestatin induces telomere dysfunction in cancer cells by removing TRF2 and POT1 from the telomeres136. In photodynamic treatment (PDT), TMPyP4 is a unique synthetic water-soluble photosensitizer with significant electron-hole transfer capacity. An inflammatory microenvironment linked with tumors is more prevalent in OS. The results showed that TMPyP4 could induce human telomeres and FAK G-quadruplexes both in vitro and in vivo. These findings indicate that TMPyP4 is a better option than cisplatin for treating OS118.

4.4. AGENTS AS TERT INHIBITORS

Human TERT contains 1,132 amino acids. The early observation that bulk tumors are often telomerase positive serves as the foundation for TERT immunotherapy. A significant finding from more recent research is that TERT plays crucial roles in every step of carcinogenesis, and its expression occurs at all stages of the cancer process, from early CSCs and/or tumor-initiating cells to advanced metastatic cancer cells96. TERT-based immunization has been demonstrated to results in tumor regression in several preclinical models. TERT-derived peptides may be identified by cytotoxic CD8+ cells in a limited MHC class I way137. Immunotherapies targeting the hTERT antigen have shown promising results and may soon be used to treat cancer126. Studies have investigated the effects of short hairpin RNAs (shRNAs) targeting hTERT on OS cell death and proliferation. It has been shown that by decreasing telomerase activity, shRNA targeting the hTERT gene may suppress cell growth and encourage OS cell death. Further studies are required to determine whether hTERT-shRNA can be used in conjunction with radiotherapy and other therapies to treat OS138. The flexible genome editing method CRISPR/Cas9 has enormous potential for cancer treatment139. Wen et al. found that inactivation of TERT is a promising cancer treatment. The scientists discovered that altering TERT affected tumor cell viability both in vitro and in vivo using the CRISPR/Cas9 gene-editing technique. Crucially, the CRISPR/Cas technology is capable of eliminating cancer cells, making it a cutting-edge and promising anti-cancer treatment that doesn't have the negative consequences of other established techniques140.

4.5. TELOMERASE-SPECIFIC ONCOLYTIC VIROTHERAPY

A potential therapy for solid tumors is oncolytic virotherapy, which employs viruses engineered to only multiply in cancer cells141. OBP-301-based, OBP-401-based, and OBP-702-based oncolytic virotherapies for the treatment of sarcomas with an invasive character would be a potential anti-cancer approach. Upon infection, OBP-301 penetrates and multiplies in tumor cells with telomerase activity because of the activation of the hTERT promoter. Subsequent stimulation of autophagy and cell lysis caused by excessive viral replication causes the virus to disseminate to nearby tumor cells. OS cells are more sensitive to doxorubicin and cisplatin in the presence of OBP-301. The upregulation of E2F1 and microRNA-29 by the adenoviral E1A protein results in the inhibition of the anti-apoptotic myeloid cell leukemia 1 protein, which is the biological mechanism responsible for OBP-301's improvement of chemosensitivity. Therefore, a potential anti-cancer approach for the treatment of OS involves a combination of OBP-301 plus chemotherapy109. OBP-301 was shown to be safe when used as monotherapy for patients with advanced solid tumors, such as LMS and neck sarcoma, according to Phase I clinical research conducted in the US142. They demonstrated the diagnostic potential of the oncolytic adenovirus OBP-401 expressing green fluorescent protein (GFP) for evaluating the sensitivity of bone and soft tissue sarcomas to viral therapy112. The effectiveness of fluorescence-guided surgery using OBP-401 for various kinds of solid tumors, such as OS and STS, has been demonstrated in vivo using preclinical tests. Specifically, in orthotopic xenograft tumor models, including human OS and fibrosarcoma cells, OBP-401-based FGS considerably decreased lung metastasis and local recurrence compared to bright-light surgery109. The GFP expression that OBP-401 mediated showed a strong correlation with OBP-401's therapeutic benefits for soft tissue and bone sarcomas in humans. ATRX is among the genes that solid tumors most frequently have mutations in, and STS are particularly prone to this mutation143. Sarcomas with ATRX deficiency and aberrant CGAS/STING signaling are sensitive to oncolytic herpes virus therapy143. An oncolytic adenovirus called OBP-702 expresses p53 and significantly activates the p53 signaling pathway. Compared with OBP-702 and OBP-301, they cause a deeper anti-tumor effect in OS cells by promoting autophagy and apoptosis. In OBP-702-infected cells, p21 suppression, induced by E1A-mediated miR-93/106b overexpression resulted in p53-mediated cell death and autophagy. A damage-regulated autophagy modulator (DRAM) was activated in response to p53 overexpression, which improves adenovirus-mediated autophagy. Furthermore, in an orthotopic MNNG/HOS xenograft tumor model resistant to OBP-301, OBP-702 inhibited tumor development. These findings imply that OBP-702-mediated p53 transactivation is a viable anti-cancer strategy that triggers autophagic and apoptotic cell death pathways in human OS cells through the control of DRAM and miRNA144. OBP-502 is a telomerase-specific replication-competent oncolytic adenovirus that binds to integrins and causes cell death. Telomerase-specific oncolytic virotherapy is a viable anti-cancer strategy that enhances the effectiveness of the PD-1 blockade in OS145. Oncolytic virotherapy targeting telomerase is currently used in clinical settings to treat patients with cancer. Oncolytic adenoviruses driven by the hTERT promoter are anticipated to provide innovative treatment options109, 122.

5. CONCLUSION AND PERSPECTIVE

The link between telomeres, telomerase, and many cellular functional pathway abnormalities associated with cancer is complex146. Telomere changes and telomerase reactivation occur frequently in sarcomas. In the future, telomeres and telomerases may be used as prognostic markers for sarcoma, and these markers may be used in the staging of patients with sarcoma for improved treatment. New treatment methods and ideas will provide a theoretical basis and direction for clinical research, which will be beneficial to overcome the challenges and shortcomings in the present treatment options. Furthermore, they will improve accuracy and effectiveness of prognosis and treatment. Despite the promise of this approach, its clinical application faces significant hurdles. Firstly, a limited number of clinical studies have been conducted thus far. Secondly, potential safety concerns and other unforeseen issues remain to be comprehensively investigated. In essence, substantial work is required before widespread clinical use.

Funding

Funding information: This work was financially funded by the National Science Foundation of China (No.81960488), The Science Foundation of Yunnan Province (Nos. 202201AT070012), The Science and Technology Innovation Team Training Project of Kunming Medical University (No. CXTD202212).

Author contributions

ZHY and ZZY contributed to conception and design. JH, YF and YJS collected and analyzed relevant literature, and wrote the manuscript. WLS and GSL conceived the structure of the article and summarized the table. GXC, YL supervised and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Our review did not require ethical approval. Correspondence and requests for materials should be addressed to Zhihong Yao.

Figure 1 Schematic representation of telomeres, the shelter complex, and telomerase.

Table 1 Sarcoma-associated activation of telomerase

Tumor type	Phenotype	Incidence rate (%)	Mechanism	Reference	
OS	hTERT positive	32		114	
ALT	11-66	TOP3A amplification	114, 147-151	
CS	hTERT mutation	43-45	The TERT promoter mutation at -124 C>T	35, 110, 152	
STS	telomerase activity	7-81		148, 153-156	
EWS	hTERT positive	12-84	fusion proteins EWS-ETS	151, 152, 157-159	
LPS	hTERT positive	18-64		99, 160	
ALT	25.9		149	
DDLPS	ALT	80	loss of either ATRX or DAXX	65, 160	
MFH	hTERT positive	22-90	p38 MAPK	151, 157	
MLS	hTERT mutation	74-77	fusion proteins FUS-DDIT3 or EWSR1-DDIT3	14, 111	
Abbreviation: Malignant Fibrous, MFH

Table 2 Targeting telomeres and telomerase in sarcomas

Target	Drug	Mechanism	Reference	
TRF1	ETP-47037 and ETP-47228	Impede TRF1 binding at the telomere point and stop the shelterin complex formation	26, 123	
TRF1 and TRF2	TeloTAC	Degradation of TRF1/2 to induce collapse of the shelter-in complex and subsequent disruption of telomerase binding to telomere ends	124	
Telomerase	BIBR1532	Non-competitive binding to the hTERT active site to inhibit telomerase	125-127	
GRN163 (Imetelstat)	Acts as a direct telomerase RNA template antagonist	125, 130, 131	
RHPS4 and TMPyP4	Disruption of the shelter-in complex, preventing telomerase from binding to telomeres	118, 133-136	
OBP-301, OBP-401, OBP-502 and OBP-702	Induction of telomerase-positive tumor cell death under the control of the hTERT promoter	109, 112, 141, 142	
TERT	GV1001, GRNVAC1	Vaccine against TERT	124
==== Refs
1 Husson O Drabbe C Schuster K van Kampen P Koops C Weidema M Setting the international research agenda for sarcoma together with patients and carers: first results of the Sarcoma Patient EuroNet (SPAEN) priority setting partnership ESMO Open 2022 7 100509 35714479
2 Crompton JG Ogura K Bernthal NM Kawai A Eilber FC Local Control of Soft Tissue and Bone Sarcomas Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2018 36 111 7 29220297
3 Mosku N Heesen P Studer G Bode B Spataro V Klass ND Biopsy Ratio of Suspected to Confirmed Sarcoma Diagnosis Cancers 2022 14
4 Grünewald TG Alonso M Avnet S Banito A Burdach S Cidre-Aranaz F Sarcoma treatment in the era of molecular medicine EMBO Mol Med 2020 12 e11131 33047515
5 Li X Seebacher NA Hornicek FJ Xiao T Duan Z Application of liquid biopsy in bone and soft tissue sarcomas: Present and future Cancer letters 2018 439 66 77 30223067
6 Dreher RD Theisen ER Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma Front Oncol 2022 12 1076581 36686841
7 Li S The basic characteristics of extracellular vesicles and their potential application in bone sarcomas J Nanobiotechnology 2021 19 277 34535153
8 Aran V Devalle S Meohas W Heringer M Cunha Caruso A Pinheiro Aguiar D Osteosarcoma, chondrosarcoma and Ewing sarcoma: Clinical aspects, biomarker discovery and liquid biopsy Crit Rev Oncol Hematol 2021 162 103340 33894338
9 Zhang C Morimoto LM de Smith AJ Hansen HM Gonzalez-Maya J Endicott AA Genetic determinants of childhood and adult height associated with osteosarcoma risk Cancer 2018 124 3742 52 30311632
10 Ji SF Wen SL Sun Y Huang PW Wu H He ML The biological function and clinical significance of STIL in osteosarcoma Cancer Cell Int 2021 21 218 33858425
11 Sung JY Lim HW Joung JG Park WY Pan-Cancer Analysis of Alternative Lengthening of Telomere Activity Cancers 2020 12
12 Rodriguez FJ Graham MK Brosnan-Cashman JA Barber JR Davis C Vizcaino MA Telomere alterations in neurofibromatosis type 1-associated solid tumors Acta Neuropathol Commun 2019 7 139 31462295
13 Flynn RL Cox KE Jeitany M Wakimoto H Bryll AR Ganem NJ Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors Science (New York, NY) 2015 347 273 7
14 Kunieda J Yamashita K Togashi Y Baba S Sakata S Inamura K High prevalence of TERT aberrations in myxoid liposarcoma: TERT reactivation may play a crucial role in tumorigenesis Cancer Sci 2022 113 1078 89 34971481
15 Ballinger ML Pattnaik S Mundra PA Zaheed M Rath E Priestley P Heritable defects in telomere and mitotic function selectively predispose to sarcomas Science (New York, NY) 2023 379 253 60
16 Robinson NJ Schiemann WP Telomerase in Cancer: Function, Regulation, and Clinical Translation Cancers 2022 14
17 Smith EM Pendlebury DF Nandakumar J Structural biology of telomeres and telomerase Cellular and molecular life sciences: CMLS 2020 77 61 79 31728577
18 Recagni M Bidzinska J Zaffaroni N Folini M The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic Implications Cancers 2020 12
19 Martínez P Blasco MA Replicating through telomeres: a means to an end Trends Biochem Sci 2015 40 504 15 26188776
20 Lim CJ Cech TR Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization Nat Rev Mol Cell Biol 2021 22 283 98 33564154
21 Ellingsen EB Mangsbo SM Hovig E Gaudernack G Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential Front Immunol 2021 12 682492 34290704
22 Weynand J Diman A Abraham M Marcélis L Jamet H Decottignies A Towards the Development of Photo-Reactive Ruthenium(II) Complexes Targeting Telomeric G-Quadruplex DNA Chemistry 2018 24 19216 27 30362627
23 Aguado J d'Adda di Fagagna F Wolvetang E Telomere transcription in ageing Ageing Res Rev 2020 62 101115 32565330
24 Ventura A Pellegrini C Cardelli L Rocco T Ciciarelli V Peris K Telomeres and Telomerase in Cutaneous Squamous Cell Carcinoma Int J Mol Sci 2019 20
25 de Lange T Shelterin-Mediated Telomere Protection Annu Rev Genet 2018 52 223 47 30208292
26 Fernandes SG Dsouza R Pandya G Kirtonia A Tergaonkar V Lee SY Role of Telomeres and Telomeric Proteins in Human Malignancies and Their Therapeutic Potential Cancers 2020 12
27 Bär C Thum T Changing Direction: From Therapeutic Telomerase Inhibition to Activation? Circ Res 2017 120 1393 5 28450362
28 Ackermann S Fischer M Telomere Maintenance in Pediatric Cancer Int J Mol Sci 2019 20
29 Webb CJ Wu Y Zakian VA DNA repair at telomeres: keeping the ends intact Cold Spring Harb Perspect Biol 2013 5
30 Hapangama DK Kamal A Saretzki G Implications of telomeres and telomerase in endometrial pathology Hum Reprod Update 2017 23 166 87 27979878
31 Bernardes de Jesus B Blasco MA Potential of telomerase activation in extending health span and longevity Curr Opin Cell Biol 2012 24 739 43 23085234
32 Gramatges MM Liu Q Yasui Y Okcu MF Neglia JP Strong LC Telomere content and risk of second malignant neoplasm in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study Clinical cancer research: an official journal of the American Association for Cancer Research 2014 20 904 11 24277454
33 Cheng F Carroll L Joglekar MV Januszewski AS Wong KK Hardikar AA Diabetes, metabolic disease, and telomere length Lancet Diabetes Endocrinol 2021 9 117 26 33248477
34 Armanios M The Role of Telomeres in Human Disease Annu Rev Genomics Hum Genet 2022 23 363 81 35609925
35 Barthel FP Wei W Tang M Martinez-Ledesma E Hu X Amin SB Systematic analysis of telomere length and somatic alterations in 31 cancer types Nat Genet 2017 49 349 57 28135248
36 Roake CM Artandi SE Regulation of human telomerase in homeostasis and disease Nat Rev Mol Cell Biol 2020 21 384 97 32242127
37 McNally EJ Luncsford PJ Armanios M Long telomeres and cancer risk: the price of cellular immortality The Journal of clinical investigation 2019 129 3474 81 31380804
38 Turner KJ Vasu V Griffin DK Telomere Biology and Human Phenotype Cells 2019 8
39 Gao J Pickett HA Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies Nature reviews Cancer 2022 22 515 32 35790854
40 De Vitis M Berardinelli F Sgura A Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT) Int J Mol Sci 2018 19
41 Bernal A Tusell L Telomeres: Implications for Cancer Development Int J Mol Sci 2018 19
42 Jafri MA Ansari SA Alqahtani MH Shay JW Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies Genome Med 2016 8 69 27323951
43 Pinzaru AM Hom RA Beal A Phillips AF Ni E Cardozo T Telomere Replication Stress Induced by POT1 Inactivation Accelerates Tumorigenesis Cell Rep 2016 15 2170 84 27239034
44 Calvete O Martinez P Garcia-Pavia P Benitez-Buelga C Paumard-Hernández B Fernandez V A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families Nat Commun 2015 6 8383 26403419
45 Shen E Xiu J Lopez GY Bentley R Jalali A Heimberger AB POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families J Med Genet 2020 57 664 70 31937561
46 Calvete O Garcia-Pavia P Domínguez F Bougeard G Kunze K Braeuninger A The wide spectrum of POT1 gene variants correlates with multiple cancer types European journal of human genetics: EJHG 2017 25 1278 81 28853721
47 Calvete O Garcia-Pavia P Domínguez F Mosteiro L Pérez-Cabornero L Cantalapiedra D POT1 and Damage Response Malfunction Trigger Acquisition of Somatic Activating Mutations in the VEGF Pathway in Cardiac Angiosarcomas J Am Heart Assoc 2019 8 e012875 31510873
48 Herrera-Mullar J Fulk K Brannan T Yussuf A Polfus L Richardson ME Characterization of POT1 tumor predisposition syndrome: Tumor prevalence in a clinically diverse hereditary cancer cohort Genetics in medicine: official journal of the American College of Medical Genetics 2023 25 100937 37466057
49 Gamboa AC Gronchi A Cardona K Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine CA Cancer J Clin 2020 70 200 29 32275330
50 Xie H Wu X Wang S Chang D Pollock RE Lev D Long telomeres in peripheral blood leukocytes are associated with an increased risk of soft tissue sarcoma Cancer 2013 119 1885 91 23408253
51 Xu Y Xu J Chancoco H Huang M Torres KE Gu J Long Leukocyte Telomere Length Is Associated with Increased Risks of Soft Tissue Sarcoma: A Mendelian Randomization Study Cancers 2020 12
52 Gocha AR Nuovo G Iwenofu OH Groden J Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies Am J Pathol 2013 182 41 8 23260199
53 Kim S Chowdhury T Yu HJ Kahng JY Lee CE Choi SA The telomere maintenance mechanism spectrum and its dynamics in gliomas Genome Med 2022 14 88 35953846
54 Liau JY Tsai JH Jeng YM Lee JC Hsu HH Yang CY Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome Am J Surg Pathol 2015 39 236 44 25229770
55 Takasugi T Gu P Liang F Staco I Chang S Pot1b -/- tumors activate G-quadruplex-induced DNA damage to promote telomere hyper-elongation Nucleic acids research 2023 51 9227 47 37560909
56 Macha SJ Koneru B Burrow TA Zhu C Savitski D Rahman RL Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function Cancer research 2022 82 3345 58 35947641
57 Chen YY Dagg R Zhang Y Lee JHY Lu R Martin La Rotta N The C-Circle Biomarker Is Secreted by Alternative-Lengthening-of-Telomeres Positive Cancer Cells inside Exosomes and Provides a Blood-Based Diagnostic for ALT Activity Cancers 2021 13
58 Sharaf R Jin DX Grady J Napier C Ebot E Frampton GM A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content NPJ genomic medicine 2023 8 26 37709802
59 Lawlor RT Veronese N Pea A Nottegar A Smith L Pilati C Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis BMC cancer 2019 19 232 30871494
60 Isakoff MS Bielack SS Meltzer P Gorlick R Osteosarcoma: Current Treatment and a Collaborative Pathway to Success Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2015 33 3029 35 26304877
61 Meltzer PS Helman LJ New Horizons in the Treatment of Osteosarcoma N Engl J Med 2021 385 2066 76 34818481
62 Chakravarti D LaBella KA DePinho RA Telomeres: history, health, and hallmarks of aging Cell 2021 184 306 22 33450206
63 Zhang C Hansen HM Semmes EC Gonzalez-Maya J Morimoto L Wei Q Common genetic variation and risk of osteosarcoma in a multi-ethnic pediatric and adolescent population Bone 2020 130 115070 31525475
64 Hoffman A Lazar AJ Pollock RE Lev D New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort Drug Resist Updat 2011 14 52 66 21169051
65 Lee JC Jeng YM Liau JY Tsai JH Hsu HH Yang CY Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2015 28 1064 73 26022452
66 Alessandrini I Percio S Naghshineh E Zuco V Stacchiotti S Gronchi A Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma Cancers 2022 14
67 Chudasama P Mughal SS Sanders MA Hübschmann D Chung I Deeg KI Integrative genomic and transcriptomic analysis of leiomyosarcoma Nat Commun 2018 9 144 29321523
68 Vertecchi E Rizzo A Salvati E Telomere Targeting Approaches in Cancer: Beyond Length Maintenance Int J Mol Sci 2022 23
69 Fernandes SG Dsouza R Khattar E External environmental agents influence telomere length and telomerase activity by modulating internal cellular processes: Implications in human aging Environ Toxicol Pharmacol 2021 85 103633 33711516
70 Kellermann G Kaiser M Dingli F Lahuna O Naud-Martin D Mahuteau-Betzer F Identification of human telomerase assembly inhibitors enabled by a novel method to produce hTERT Nucleic Acids Res 2015 43 e99 25958399
71 Rosen J Jakobs P Ale-Agha N Altschmied J Haendeler J Non-canonical functions of Telomerase Reverse Transcriptase - Impact on redox homeostasis Redox Biol 2020 34 101543 32502898
72 Dratwa M Wysoczańska B Łacina P Kubik T Bogunia-Kubik K TERT-Regulation and Roles in Cancer Formation Front Immunol 2020 11 589929 33329574
73 Wang Y Sušac L Feigon J Structural Biology of Telomerase Cold Spring Harb Perspect Biol 2019 11
74 Miracco EJ Jiang J Cash DD Feigon J Progress in structural studies of telomerase Curr Opin Struct Biol 2014 24 115 24 24508601
75 Yuan X Larsson C Xu D Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players Oncogene 2019 38 6172 83 31285550
76 Sharma S Chowdhury S Emerging mechanisms of telomerase reactivation in cancer Trends Cancer 2022 8 632 41 35568649
77 Nault JC Ningarhari M Rebouissou S Zucman-Rossi J The role of telomeres and telomerase in cirrhosis and liver cancer Nat Rev Gastroenterol Hepatol 2019 16 544 58 31253940
78 Arndt GM MacKenzie KL New prospects for targeting telomerase beyond the telomere Nature reviews Cancer 2016 16 508 24 27339602
79 Wu L Fidan K Um JY Ahn KS Telomerase: Key regulator of inflammation and cancer Pharmacol Res 2020 155 104726 32109579
80 Akıncılar SC Chua JYH Ng QF Chan CHT Eslami SZ Chen K Identification of mechanism of cancer-cell-specific reactivation of hTERT offers therapeutic opportunities for blocking telomerase specifically in human colorectal cancer Nucleic Acids Res 2022
81 Akıncılar SC Khattar E Boon PL Unal B Fullwood MJ Tergaonkar V Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation Cancer Discov 2016 6 1276 91 27650951
82 Zhu GG Nafa K Agaram N Zehir A Benayed R Sadowska J Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma Clinical cancer research: an official journal of the American Association for Cancer Research 2020 26 419 27 31615936
83 Cross W Lyskjær I Lesluyes T Hargreaves S Strobl AC Davies C A genetic model for central chondrosarcoma evolution correlates with patient outcome Genome Med 2022 14 99 36042521
84 Dermawan JK Hwang S Wexler L Tap WD Singer S Vanderbilt CM Myxoid pleomorphic liposarcoma is distinguished from other liposarcomas by widespread loss of heterozygosity and significantly worse overall survival: a genomic and clinicopathologic study Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2022 35 1644 55 35672466
85 Yoshuantari N Jeng YM Liau JY Lee CH Tsai JH Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2023 36 100042 36788061
86 Griewank KG Wiesner T Murali R Pischler C Müller H Koelsche C Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2018 31 418 28 29099504
87 Ferreira MSV Crysandt M Braunschweig T Jost E Voss B Bouillon AS Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas Int J Mol Sci 2018 19
88 Lucas CG Grenert JP Horvai A Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma Arch Pathol Lab Med 2021 145 1009 17 33147331
89 Zaki MM Mashouf LA Woodward E Langat P Gupta S Dunn IF Genomic landscape of gliosarcoma: distinguishing features and targetable alterations Sci Rep 2021 11 18009 34504233
90 Leão R Apolónio JD Lee D Figueiredo A Tabori U Castelo-Branco P Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer J Biomed Sci 2018 25 22 29526163
91 Alessandrini I Recagni M Zaffaroni N Folini M On the Road to Fight Cancer: The Potential of G-quadruplex Ligands as Novel Therapeutic Agents Int J Mol Sci 2021 22
92 Gala K Khattar E Long non-coding RNAs at work on telomeres: Functions and implications in cancer therapy Cancer letters 2021 502 120 32 33450357
93 Ebata H Loo TM Takahashi A Telomere Maintenance and the cGAS-STING Pathway in Cancer Cells 2022 11
94 Wu RA Upton HE Vogan JM Collins K Telomerase Mechanism of Telomere Synthesis Annu Rev Biochem 2017 86 439 60 28141967
95 Smith S Telomerase can't handle the stress Genes Dev 2018 32 597 9 29802121
96 Zanetti M A second chance for telomerase reverse transcriptase in anticancer immunotherapy Nat Rev Clin Oncol 2017 14 115 28 27245281
97 Parks JW Stone MD Single-Molecule Studies of Telomeres and Telomerase Annu Rev Biophys 2017 46 357 77 28375735
98 He Y Feigon J Telomerase structural biology comes of age Curr Opin Struct Biol 2022 76 102446 36081246
99 Bajaj S Kumar MS Peters GJ Mayur YC Targeting telomerase for its advent in cancer therapeutics Med Res Rev 2020 40 1871 919 32391613
100 Yuan X Dai M Xu D TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends Cancer letters 2020 493 1 9 32768523
101 Lipinska N Romaniuk A Paszel-Jaworska A Toton E Kopczynski P Rubis B Telomerase and drug resistance in cancer Cellular and molecular life sciences: CMLS 2017 74 4121 32 28623509
102 Maciejowski J de Lange T Telomeres in cancer: tumour suppression and genome instability Nat Rev Mol Cell Biol 2017 18 175 86 28096526
103 Guterres AN Villanueva J Targeting telomerase for cancer therapy Oncogene 2020 39 5811 24 32733068
104 Monsen RC DeLeeuw L Dean WL Gray RD Sabo TM Chakravarthy S The hTERT core promoter forms three parallel G-quadruplexes Nucleic Acids Res 2020 48 5720 34 32083666
105 Bettegowda C Yip S Jiang B Wang WL Clarke MJ Lazary A Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas Neuro Oncol 2019 21 1005 15 30976795
106 Penev A Bazley A Shen M Boeke JD Savage SA Sfeir A Alternative splicing is a developmental switch for hTERT expression Mol Cell 2021 81 2349 60.e6 33852895
107 McKelvey BA Umbricht CB Zeiger MA Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review Front Endocrinol (Lausanne) 2020 11 485 32849278
108 Yasukawa M Ando Y Yamashita T Matsuda Y Shoji S Morioka MS CDK1 dependent phosphorylation of hTERT contributes to cancer progression Nat Commun 2020 11 1557 32214089
109 Tazawa H Hasei J Yano S Kagawa S Ozaki T Fujiwara T Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy Cancers 2020 12
110 Zhang Y Chen Y Yang C Seger N Hesla AC Tsagkozis P TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2021 34 2020 7 34108637
111 Koelsche C Renner M Hartmann W Brandt R Lehner B Waldburger N TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities Journal of experimental & clinical cancer research: CR 2014 33 33 24726063
112 Uotani K Tazawa H Hasei J Fujiwara T Yoshida A Yamakawa Y Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus PLoS One 2024 19 e0298292 38377118
113 Lin Y Seger N Chen Y Hesla AC Wejde J Ghaderi M hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2018 31 1834 41 30065261
114 Sanders RP Drissi R Billups CA Daw NC Valentine MB Dome JS Telomerase expression predicts unfavorable outcome in osteosarcoma Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2004 22 3790 7 15365076
115 Wei G Peng Z Liu J Yang K Zhao C Xie W Accurate Identification and Early Diagnosis of Osteosarcoma through CRISPR-Cas12a-Based Average Telomerase Activity Detection ACS synthetic biology 2021 10 2409 16 34495650
116 Linch M Miah AB Thway K Judson IR Benson C Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies Nat Rev Clin Oncol 2014 11 187 202 24642677
117 Frezza AM Stacchiotti S Gronchi A Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new BMC Med 2017 15 109 28571564
118 Chen J Jin X Mei Y Shen Z Zhu J Shi H The different biological effects of TMPyP4 and cisplatin in the inflammatory microenvironment of osteosarcoma are attributed to G-quadruplex Cell Prolif 2021 54 e13101 34296479
119 Gill J Gorlick R Advancing therapy for osteosarcoma Nat Rev Clin Oncol 2021 18 609 24 34131316
120 Yaswen P MacKenzie KL Keith WN Hentosh P Rodier F Zhu J Therapeutic targeting of replicative immortality Semin Cancer Biol 2015 35 Suppl S104 s28 25869441
121 In der Stroth L Tharehalli U Günes C Lechel A Telomeres and Telomerase in the Development of Liver Cancer Cancers 2020 12
122 Sasaki T Tazawa H Hasei J Kunisada T Yoshida A Hashimoto Y Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas Clinical cancer research: an official journal of the American Association for Cancer Research 2011 17 1828 38 21325287
123 Martínez P Blasco MA Telomere-driven diseases and telomere-targeting therapies The Journal of cell biology 2017 216 875 87 28254828
124 Wang Z Liu J Chen H Qiu X Xie L Kaniskan H Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins J Am Chem Soc 2023 145 10872 9 37141574
125 Ruden M Puri N Novel anticancer therapeutics targeting telomerase Cancer treatment reviews 2013 39 444 56 22841437
126 Saraswati AP Relitti N Brindisi M Gemma S Zisterer D Butini S Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors Drug Discov Today 2019 24 1370 88 31136800
127 Parsch D Brassat U Brümmendorf TH Fellenberg J Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines Cancer investigation 2008 26 590 6 18584350
128 Asai A Oshima Y Yamamoto Y Uochi TA Kusaka H Akinaga S A novel telomerase template antagonist (GRN163) as a potential anticancer agent Cancer research 2003 63 3931 9 12873987
129 Eckburg A Dein J Berei J Schrank Z Puri N Oligonucleotides and microRNAs Targeting Telomerase Subunits in Cancer Therapy Cancers 2020 12
130 Thompson PA Drissi R Muscal JA Panditharatna E Fouladi M Ingle AM A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112) Clinical cancer research: an official journal of the American Association for Cancer Research 2013 19 6578 84 24097866
131 Hu Y Bobb D He J Hill DA Dome JS The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma Cancer Biol Ther 2015 16 949 57 25920748
132 Trieb K Thurnher D Bakroeva M Kotz R Kornfehl J Reversible downregulation of telomerase activity by hyperthermia in osteosarcoma cells International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2000 16 445 8 11001578
133 Amato R Valenzuela M Berardinelli F Salvati E Maresca C Leone S G-quadruplex Stabilization Fuels the ALT Pathway in ALT-positive Osteosarcoma Cells Genes 2020 11
134 Awadasseid A Ma X Wu Y Zhang W G-quadruplex stabilization via small-molecules as a potential anti-cancer strategy Biomed Pharmacother 2021 139 111550 33831835
135 Jamroskovic J Doimo M Chand K Obi I Kumar R Brännström K Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization J Am Chem Soc 2020 142 2876 88 31990532
136 Seimiya H Crossroads of telomere biology and anticancer drug discovery Cancer Sci 2020 111 3089 99 32579791
137 Mocellin S Pooley KA Nitti D Telomerase and the search for the end of cancer Trends Mol Med 2013 19 125 33 23253475
138 Chen P Gu WL Gong MZ Wang J Li DQ shRNA-mediated silencing of hTERT suppresses proliferation and promotes apoptosis in osteosarcoma cells Cancer Gene Ther 2017 24 325 32 28799566
139 Liang C Li F Wang L Zhang ZK Wang C He B Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma Biomaterials 2017 147 68 85 28938163
140 Porika M Tippani R Saretzki GC CRISPR/Cas: A New Tool in the Research of Telomeres and Telomerase as Well as a Novel Form of Cancer Therapy Int J Mol Sci 2022 23
141 Morales-Molina A Gambera S Leo A García-Castro J Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma J Immunother Cancer 2021 9
142 Nemunaitis J Tong AW Nemunaitis M Senzer N Phadke AP Bedell C A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors Molecular therapy: the journal of the American Society of Gene Therapy 2010 18 429 34 19935775
143 Floyd W Pierpoint M Su C Patel R Luo L Deland K Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus The Journal of clinical investigation 2023 133
144 Hasei J Sasaki T Tazawa H Osaki S Yamakawa Y Kunisada T Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells Molecular cancer therapeutics 2013 12 314 25 23315976
145 Mochizuki Y Tazawa H Demiya K Kure M Kondo H Komatsubara T Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma Cancer immunology, immunotherapy: CII 2021 70 1405 17 33151368
146 Alnafakh RAA Adishesh M Button L Saretzki G Hapangama DK Telomerase and Telomeres in Endometrial Cancer Front Oncol 2019 9 344 31157162
147 de Nonneville A Salas S Bertucci F Sobinoff AP Adélaïde J Guille A TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT EMBO molecular medicine 2022 14 e15859 35920001
148 Henson JD Hannay JA McCarthy SW Royds JA Yeager TR Robinson RA A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas Clinical cancer research: an official journal of the American Association for Cancer Research 2005 11 217 25 15671549
149 Costa A Daidone MG Daprai L Villa R Cantù S Pilotti S Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression Cancer research 2006 66 8918 24 16951210
150 Ulaner GA Huang HY Otero J Zhao Z Ben-Porat L Satagopan JM Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma Cancer research 2003 63 1759 63 12702558
151 Sotillo-Piñeiro E Sierrasesúmaga L Patiñno-García A Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients Pediatric research 2004 55 231 5 14630995
152 Umehara N Ozaki T Sugihara S Kunisada T Morimoto Y Kawai A Influence of telomerase activity on bone and soft tissue tumors Journal of cancer research and clinical oncology 2004 130 411 6 15160288
153 Lauer NK Maier SM Oberringer M Schulte M Mutschler W Hanselmann RG Absence of telomerase activity in malignant bone tumors and soft-tissue sarcomas Sarcoma 2002 6 43 6 18521344
154 Schneider-Stock R Rys J Jaeger V Niezabitowski A Kruczak A Sokolowski A Prognostic significance of telomerase activity in soft tissue sarcomas International journal of oncology 1999 15 775 80 10493961
155 Terasaki T Kyo S Takakura M Maida Y Tsuchiya H Tomita K Analysis of telomerase activity and telomere length in bone and soft tissue tumors Oncology reports 2004 11 1307 11 15138570
156 Matsuo T Shay JW Wright WE Hiyama E Shimose S Kubo T Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas The Journal of bone and joint surgery American volume 2009 91 928 37 19339578
157 Fuchs B Inwards C Scully SP Janknecht R hTERT Is highly expressed in Ewing's sarcoma and activated by EWS-ETS oncoproteins Clinical orthopaedics and related research 2004 64 8
158 Ulaner GA Hoffman AR Otero J Huang HY Zhao Z Mazumdar M Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas Genes, chromosomes & cancer 2004 41 155 62 15287028
159 Tomoda R Seto M Tsumuki H Iida K Yamazaki T Sonoda J Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors Cancer 2002 95 1127 33 12209700
160 Patel RM Folpe AL Immunohistochemistry for human telomerase reverse transcriptase catalytic subunit (hTERT): a study of 143 benign and malignant soft tissue and bone tumours Pathology 2009 41 527 32 19900100
